The Inhibition of Calcium Oxalate Crystal Growth by Chondroitin Sulphates, Heparin, Pentosan Polysulphate and Tamm-Horsfall Glycoprotein

  • B. Fellström
  • B. G. Danielson
  • S. Ljunghall
  • B. Wikström

Abstract

A large number of the urinary constituents have been reported to inhibit calcium oxalate crystal growth and aggregation. Pyrophosphate, for example, is a potent inhibitor of crystal growth1 and glycosaminoglycans potent inhibitors of crystal aggregation2. Regarding urinary macromolecular inhibitors of calcium oxalate crystallization, a number of substances such as glycosaminoglycans2, polypeptides3, polyribonucleotides4 and glycoproteins5 have been claimed to be of importance. There has also been a debate as to whether uromucoid or Tamm-Horsfall glycoprotein is a promoter or an inhibitor of the crystallization process6. The purpose of the present study is to compare the inhibition of calcium oxalate crystal growth by pyrophosphate, polyanionic glycosaminoglycans and Tamm-Horsfall glycoprotein. This comparison has also been extended to include two drugs with a structure similar to pyrophosphate and heparin respectively.

Keywords

Crystallization Heparin Polypeptide Oxalate Pyrophosphate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L. H. Smith, J. L. Meyer and J. T. McCall, in: “Urinary Calculi”, L. Cifuentes Delatte, A. Rapado, and A. Hodgkinson, eds., Karger, Basel (1973).Google Scholar
  2. 2.
    W. G. Robertson, M. Peacock, and B. E. C. Nordin, Clin. Chim. Acta 43:31 (1973).PubMedCrossRefGoogle Scholar
  3. 3.
    H. Ito and F. L. Coe, Am. J. Physiol. 233:F455 (1977).PubMedGoogle Scholar
  4. 4.
    E. E. Schrier, K. E. Lee, J. L. Rubin, P. G. Werness, and L. H. Smith, in: “Oxalate in Human Biochemistry and Clinical Pathology”, G. A. Rose, W. G. Robertson, and R. W. E. Watts, eds., Wellcome Foundation, London (1979).Google Scholar
  5. 5.
    T. Kitamura, J. E. Zerwekh, and C. Y. C. Pak, Kidney Int. 21:379 (1982).PubMedCrossRefGoogle Scholar
  6. 6.
    T. Kitamura and C. Y. C. Pak, J. Urol. 127:1024 (1982).PubMedGoogle Scholar
  7. 7.
    B. Fellström, U. Backman, B. G. Danielson, K. Holmgren, S. Ljunghall, and B. Wikström, Clin. Sci. 62:509 (1982).PubMedGoogle Scholar
  8. 8.
    I. Tamm and F. L. Horsfall, J. Exp. Med. 95:71 (1952).PubMedCrossRefGoogle Scholar
  9. 9.
    B. Fellström, B. G. Danielson, S. Ljunghall, and B. Wikström, in: “Urolithiasis and Related Clinical Research”, P. O. Schwüle, L. H. Smith, W. G. Robertson, and W. Vahlensieck, eds., Plenum, New York (1985).Google Scholar
  10. 10.
    W. D. Comper and T. C. Laurent, Physiol. Rev. 58:255 (1978).PubMedGoogle Scholar
  11. 11.
    B. Fellström, B. G. Danielson, F. A. Karlsson, and S. Ljunghall, in: “Urolithiasis and Related Clinical Research”, P. O. Schwille, L. H. Smith, W. G. Robertson, and W. Vahlensieck, eds., Plenum, New York (1985).Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • B. Fellström
    • 1
  • B. G. Danielson
    • 1
  • S. Ljunghall
    • 1
  • B. Wikström
    • 1
  1. 1.Dept. of Internal MedicineUniversity HospitalUppsalaSweden

Personalised recommendations